{"entity":{"id":"dat-2645","kind":"drug","name":"DAT-2645","aka":[],"tldr":"DAT-2645 is an experimental small molecule from Danatlas Pharmaceuticals, in phase 2 trials for solid tumours with BRCA1/2 or DNA damage repair defects and BRCA-mutated or HRD-positive ovarian cancer.","summary":"DAT-2645 is a small molecule (oral tablet) from Danatlas Pharmaceuticals. An oral PARG inhibitor for tumours with BRCA1/2 loss of function or other DNA damage repair defects. Its furthest stage is phase 2, for solid tumours with BRCA1/2 or DNA damage repair defects and BRCA-mutated or HRD-positive ovarian cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06614751 and phase 2 NCT07652073 both not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Danatlas Pharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06614751"},{"label":"Danatlas Pharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07652073"},{"label":"ClinicalTrials.gov: trials of DAT-2645","url":"https://clinicaltrials.gov/search?intr=DAT-2645"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["parg"],"drugs":[],"companies":["danatlas-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06614751","nct07652073"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DAT-2645","modality":"Small molecule (oral tablet)","mechanism":"An oral PARG inhibitor for tumours with BRCA1/2 loss of function or other DNA damage repair defects.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dat-2645/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"parg","kind":"target","name":"PARG","route":"/targets/parg/"}],"company":[{"id":"danatlas-pharmaceuticals","kind":"company","name":"Danatlas Pharmaceuticals","route":"/companies/danatlas-pharmaceuticals/"}],"trial":[{"id":"nct06614751","kind":"trial","name":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","route":"/trials/nct06614751/"},{"id":"nct07652073","kind":"trial","name":"A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer","route":"/trials/nct07652073/"}]}}